European guidance for the diagnosis and management of osteoporosis in postmenopausal women

Erratum to: Osteoporosis Int

DOI 10.1007/s00198-008-0560-z

In the last row of Table 7, the fracture incidence data for the placebo and drug groups were the wrong way around. The correct rates are 2.5% for the placebo group and 1.4% for the zoledronic acid group. The corrected table is reproduced here.

Table 7 Study details and antifracture efficacy (relative risk [RR] and 95% confidence intervals [CI]) of the major pharmacological treatments used for postmenopausal osteoporosis when given with calcium and vitamin D, as derived from randomized controlled trials